moa of glp 1 agonists Non-insulin injectable antidiabetic drugs - GLP-1 and amylinomimetics Understanding GLP-1 Agonists - YouTube

Conclusion This study elucidates causal relationships between biomarkers, dietary habits, and DR progression, emphasizing the potential for personalized dietary interventions to prevent or manage DR

Tracy TS, Wirthwein DP, Hall SD

Safety and translational challenges are considerable and must drive clinical application: immune stimulation carries theoretical risk as well as known risk of worsening autoimmune phenomena or inflammatory toxicities, particularly in the setting of active immunosuppression (e.g., newly diagnosed with cytotoxic therapy, on high-dose steroids)

Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M